AZ AstraZeneca
Bladder
For Educational Purposes Only

Advancing Bladder Cancer Together

Treatment of early-stage (NMIBC) and advanced (MIBC) Bladder Cancer

AUA 2026 Updates

POTOMAC: Time to High-Risk Disease Event

MEDIAN TIME TO HIGH-RISK EVENT14.1monthsIMFINZI + BCGvs8.3monthsBCG ALONE
EVENTS WITHIN FIRST YEAR (% OF PATIENTS WITH EVENTS)IMFINZI + BCG (N=339)BCG alone (N=340)≤ 3 months13%20%≤ 6 months26%42%≤ 12 months45%61%
PATIENTS WITH HIGH-RISK DISEASE EVENT53/339 (16%)vs69/340 (20%)
High-risk disease event defined as: high-risk NMIBC recurrence (high-grade Ta, T1, or CIS), persistent CIS at 6 months, MIBC, and/or metastatic disease.

Time to high-risk disease event analyses are exploratory and were not powered to determine statistical significance. Post hoc exploratory analysis. Data cutoff April 3, 2025.

POTOMAC · AUA 2026 · Exploratory Analysis

POTOMAC: DFS in Patients With T1 Disease

45%REDUCTION IN RISK OF RECURRENCE OFHIGH-RISK DISEASE OR DEATHwith IMFINZI + BCGHR = 0.55(95% CI: 0.31–0.94)
Probability of DFS1.00.80.60.40.20012243648607278Time from randomization (months)87%76%83%72%83%72%IMFINZI + BCG (n=102)BCG alone (n=114)I+BBCG9789868683838280797775737271706964624645353120114110698968887848077777471686868686863585246312515930No. at risk
IMFINZI + BCG (n=102)BCG alone (n=114)Events, n (%)19 (19%)vs36 (32%)Median DFS (95% CI)NR (NR–NR)74.0 (68.1–NR)

The DFS in the subgroups of patients with T1 tumors was not powered to show differences between or within individual subgroups and was not powered for statistical significance.

POTOMAC · AUA 2026 · T1 HG/G3 Subgroup

POTOMAC: DFS — T1 Subgroup Analysis

Probability of DFS1.00.80.60.40.20012243648607278Time from randomization (months)87%76%83%72%83%72%IMFINZI + BCG (n=102)BCG alone (n=114)I+BBCG9789868683838280797775737271706964624645353120114110698968887848077777471686868686863585246312515930No. at risk
DFS IN T1 SUBGROUPS Any T1 T1 Only T1 HG/G3 IMFINZI + BCG (events/patients) 35/195 (18%) 22/137 (16%) 19/102 (19%) BCG alone (events/patients) 66/211 (31%) 45/145 (31%) 36/114 (32%) HR (95% CI) 0.55 (0.36–0.82) 0.48 (0.28–0.79) 0.55 (0.31–0.95) % of ITT population: 58–62% 40–43% 30–34%

Post hoc exploratory analysis. Data cutoff April 3, 2025. Not powered for statistical significance.

POTOMAC · AUA 2026 · T1 Subgroup Analysis

POTOMAC: Time to Cystectomy

MEDIAN TIME TO CYSTECTOMY19.0months · IMFINZI + BCGvs14.1months · BCG alone
IMFINZI + BCG (n=13)0612182430364248Median: 19.0 moBCG alone (n=21)0612182430364248Median: 14.1 moTime from randomization (months)
TIME TO CYSTECTOMY — ITT POPULATIONNCystectomy, n (%)Median, months(95% CI)HR (95% CI)IMFINZI + BCG33913 (4%)NR (NR–NR)0.63BCG alone34021 (6%)NR (NR–NR)(0.31–1.24)
PATIENTS WHO UNDERWENT CYSTECTOMY(among patients with a high-risk disease event)8%IMFINZI + BCG2 of 24 patientsvs25%BCG alone11 of 44 patients

Time to cystectomy analyses are exploratory and were not powered to determine statistical significance. Post hoc analysis. Data cutoff April 3, 2025.

POTOMAC · AUA 2026 · Time to Cystectomy

POTOMAC: AUA 2026 Wrap-Up

For further information on the full POTOMAC data presented at AUA 2026, access the official resources below.

Access POTOMAC · AUA 2026 Resources
Coming Next
Coming Soon

New Data at ESMO 2026

Stay tuned for the next update in bladder cancer — new data and insights coming to ESMO 2026.

POTOMAC · AUA 2026 · Stay Tuned for ESMO